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Abstract
Background: SARS coronavirus main proteinase (SARS CoVMpro) is an important enzyme for
the replication of Severe Acute Respiratory Syndrome virus. The active site region of SARS
CoVMpro is divided into 8 subsites. Understanding the binding mode of SARS CoVMpro with a
specific substrate is useful and contributes to structural-based drug design. The purpose of this
research is to investigate the binding mode between the SARS CoVMpro and two octapeptides,
especially in the region of the S3 subsite, through a molecular docking and molecular dynamics
(MD) simulation approach.
Results: The one turn α-helix chain (residues 47–54) of the SARS CoVMpro was directly
involved in the induced-fit model of the enzyme-substrate complex. The S3 subsite of the
enzyme had a negatively charged region due to the presence of Glu47. During MD simulations,
Glu47 of the enzyme was shown to play a key role in electrostatic bonding with the P3Lys of the
octapeptide.
Conclusion: MD simulations were carried out on the SARS CoVMpro-octapeptide complex.
The hypothesis proposed that Glu47 of SARS CoVMpro is an important residue in the S3 subsite
and is involved in binding with P3Lys of the octapeptide.
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Background
The human coronavirus is a major cause of respiratory
syndrome and in particular of a disease called Severe
Acute Respiratory Syndrome (SARS). This disease spread
rapidly from China to several countries during 2003. The
enzyme called Severe Acute Respiratory Syndrome Coro-
navirus Main Proteinase (SARS CoVMpro) is an important
enzyme involved in the life cycle of the human coronavi-
rus. The crystal structure of the SARS CoVMpro complexed
to the inhibitor has been solved previously [1-5]. This
enzyme is a member of the cysteine proteinases and
exhibits the typical catalytic diad, cysteine and histidine,
in the active site [6-12]. Previous studies on substrate spe-
cificity indicated that the active site, including the binding
site, of the SARS CoVMpro could bind specifically to a
substrate containing 8 amino acids. These positions in the
octapeptide were termed P5-P4-P3-P2-P1-P1'-P2'-P3' and
the sequence Ser-Ala-Val-Leu-Gln-Ser-Gly-Phe. This
sequence is optimal for the proteinase from Transmissible
Gastro Enteritis Virus (TGEV), but it is unsuitable for SARS
CoVMpro [7]. Recently, investigations of substrate specif-
icity against SARS CoVMpro proposed that the octapep-
tides with sequences of Ser-Ala-Val-Leu-Gln-Ala-Gly-Phe
and Thr-Val-Lys-Leu-Gln-Ser-Gly-Phe are optimal for
cleavage by SARS CoVMpro. It is interesting to note that
when the P3 position of this latter octapeptide was
changed from Val to Lys it caused an increase in the rate
of catalysis (kcat/Km) of the SARS CoVMpro of 4.31 fold
[13]. However, information on interactions between
P3Lys of the octapeptide and the S3 subsite of the SARS
CoVMpro remain unclear. Therefore, our research intends
to study the interactions between P3Lys and the S3 subsite
in order to investigate the amino acids in the S3 subsite
that are critical for binding P3Lys of the octapeptide. In
addition, the two octapeptides Thr-Val-Arg-Leu-Gln-Ala-
Gly-Phe and Thr-Val-Ile-Leu-Gln-Ala-Gly-Phe were used
to investigate these interactions. At the P3 position these
octapeptides contained either a long chain positive charge
or an aliphatic hydrophobic amino acid. This was pro-
posed to prove that the P3Lys is a significant amino acid
for binding in the S3 subsite of the SARS CoVMpro. Thus,
molecular modeling techniques can be used to clarify this
problem [14,15]. In the present paper, we present the 2 ns
conventional MD simulation of the SARS CoVMpro com-
plexed with the octapeptide and compare this to an
uncomplexed SARS CoVMpro, with the purpose of inves-
tigating the amino acids in each subsite, and especially S3,
which are crucial to increasing the substrate binding.
Hence, the results obtained from this research are very
important in the understanding of the binding mecha-
nism and catalytic mechanism of the SARS CoVMpro.
Methods
Visualization and computational
All steps in this research were performed in silico using
molecular modeling software. Preparation of all three-
dimensional structures used Insight II (version 2001)
from Accelrys [16]. Molecular docking and molecular
dynamics (MD) simulations used Autodock 3.0.5, Auto-
dockTools and GROMACS 3.3.1 [17-19]. The results of
molecular docking and MD simulations were analyzed
using Discovery Studio 2.0.1 [16]. All of the calculations
were performed on a 48 processor Itanium cluster at the
National Electronic and Computer Technology Center
(NECTEC), Thailand.
Preparation the structures of the SARS CoVMpro and the 
octapeptide
The structure of the SARS CoVMpro was taken from the
Brookhaven protein data bank using the PDB code
1UK4[10]. The structure was checked and the missing
atoms replaced using the Builder module of the Insight II.
The polar hydrogen atoms were added followed by energy
minimization in vacuo with steepest descent method for
1,000 steps. The final structure obtained from energy min-
imization was used in all further steps. The structures of
the octapeptides were prepared based on the research of
Fan et al. [13]. Three octapeptides were constructed,
including hydrogen atoms, by using the Builder module
and the following sequences: Thr-Val-Lys-Leu-Gln-Ala-
Gly-Phe, Thr-Val-Arg-Leu-Gln-Ala-Gly-Phe and Thr-Val-
Ile-Leu-Gln-Ala-Gly-Phe. These structures only differed at
the P3 position. All of the structures were subjected to
energy minimization in the same manner as that for SARS
CoVMpro. The structures obtained from energy minimi-
zation were utilized for further docking studies.
Structure refinement
For this research, the structure of the SARS CoVMpro was
prepared in the catalytically competent conformation. It is
believed that this structure was in the natural form and
ready for substrate catalysis [14,15]. Firstly, the structure
of the SARS CoVMpro, obtained from the energy minimi-
zation, was subjected to primary MD simulation. To per-
form MD simulation the structure of the enzyme was set
to the GROMOS96 43a1 force field with explicit hydrogen
atoms in the aromatic rings. The simulation cell was cre-
ated in a cubic periodic box with a minimum distance of
0.9 Å between the protein and the box walls. The enzyme
was soaked with approximately 40,000 water molecules
defined using the simple point charges (SPC) of water
model. The Glu and Asp of the SARS CoVMpro were set a
charge of -1. Lys was set a charge of +1. His had an added
hydrogen atom at the B position. As the total charge of the
system was -6, six atoms of Na+ were added to the system
to adjust the charge to neutral. Electrostatic interactions
between charged groups at a distance of less than 3 Å wereBMC Bioinformatics 2009, 10(Suppl 1):S48 http://www.biomedcentral.com/1471-2105/10/S1/S48
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calculated explicitly. Energy minimization was performed
by using 1,000 steps of steepest descent method. Long-
range electrostatic interactions were calculated using the
Particle-Mesh Ewald method (PME) with a grid width of
1.2 Å and a fourth-order spline interpolation. A cutoff dis-
tance of 9 Å was applied for Lennard-Jones interactions.
To maintain the system at a constant temperature of 300
K, a Berendsen thermostat was applied using a coupling
time of 0.1 ps. Pressure was held at 1 bar, with a coupling
time of 1 ps. The time step was set as 2 fs and the simula-
tion performed for 100 ps. The structure of the SARS
CoVMpro obtained at the last time point (100 ps) was
selected for further molecular docking studies.
Molecular docking studies
In the molecular docking, the interaction between the
SARS CoVMpro and the three octapeptides were investi-
gated. The structure of the enzyme obtained from the final
step of structure refinement and the structures of the
ocapeptide obtained from energy minimization were used
in all steps. The calculations employed a Lamarckian
Genetic Algorithm (LGA) with partial flexible rotatable
bonds. The structure of the octapeptide was defined as 19
rotatable bonds, situated along the backbone, by fixing
the position of the side chains. The grid points for Autog-
rid calculations were set to be 80 × 80 × 80 Å with the sul-
fur atom of SARS CoVMpro Cys145 assigned as the center
of the grid box. The docking parameters were set to a LGA
calculation of 1,000 runs. The energy evaluations were set
to 1,500,000 and 27.000 generations. Population size was
set to 100 and the rate of gene mutation and the rate of
gene crossover were set to 0.02 and 0.8 respectively. At the
end of the calculations, the obtained conformations were
summarized, collected and extracted using the Autodock-
Tool. The docked conformations were clustered by set the
Root Mean Square Deviation (RMSD) as 2.0 Å. The first
ranked presented the highest members was selected. The
conformation that exhibited the lowest docking energy in
that cluster was selected for analysis and further MD sim-
ulation.
Molecular dynamics simulation
In order to perform molecular dynamics simulations,
three structures of the SARS CoVMpro complexed with the
octapeptides obtained from the docking, were prepared.
The parameters of the simulation were adjusted to be the
same as in the structure refinement step described above.
However, one atom of the Na+ was also added in each sys-
tem of the enzyme-substrate complexed of the octapep-
tide P3Lys and P3Arg due to it neutralized the amino acid,
Lys and Arg. In the simulation, each time step was set to 2
fs and the simulation of the whole system performed for
2,000 ps (2 ns). The structure of the enzyme-substrate
complexes were extracted every 1 ps for analysis.
Data analysis
The results of simulations with each structure were com-
pared against each other. Values of the root mean square
deviation (RMSD) and the root mean square fluctuation
(RMSF) were monitored during the simulations. These
values were the criteria used to describe the motion of the
protein chains, including the amino acids, in the active
site of the SARS CoVMpro. The atomic distances and
number of hydrogen bonds were also investigated to
explain the interaction between the SARS CoVMpro and
the octapeptide in the enzyme-substrate complex.
Results and discussion
Catalytically competent conformation of the SARS 
CoVMpro
The active site region of the SARS CoVMpro was com-
posed of 7 protein chains: chain 1, residues 19–28; chain
2, residues 41–54; chain 3, residues 67–70; chain 4, resi-
dues 117–120; chain 5, residues 139–145; chain 6, resi-
dues 163–172 and chain7, residues 187–192. Among
them, chain 2 was called the one turn α-helix and chain 7
was called the long loop. Previous research has deter-
mined the equilibrium point of the system of the SARS
CoVMpro free form, and found that the enzyme reached
equilibrium after 400 ps [14,15]. Therefore, initially in
this research, MD simulation of the dimer structure of the
SARS CoVMpro free form was performed for 500 ps (Fig-
ure 1). Then, the structure of the enzyme was snapshot
and the new confirmation compared to the starting struc-
ture. It had a different conformation in the active site
caused by movement of the one turn α-helix and the long
loop chain of the enzyme. The RMSD value was calculated
from this comparison and was 2.62 Å. This result indi-
cated that the structure of the SARS CoVMpro and, in par-
ticular, the active site obtained from this research differed
from the crystal structure. However, this new structure was
considered an acceptable conformation for further dock-
ing and MD simulation, since the orientation of the pro-
tein chains in the active site were consistent with
previously reported research [7,15,20,21]. During simula-
tion, the protein one turn α-helix and long loop chain
stretched their backbone. This movement resulted in an
"open mouth" catalytic cleft between domain I and
domain II [15]. This phenomenon is the catalytically
competent conformation of the SARS CoVMpro and this
structure was used for further docking and MD simula-
tion.
Docking studies
The active site of the SARS CoVMpro was divided into 8
subsites. Thus, the subsites namely S5-S4-S3-S2-S1-S1'-
S2'-S3' accommodated the corresponding peptide resi-
dues named P3-P2-P1-P1'-P2'-P3', respectively. It is
known that the S2 subsite is a hydrophobic pocket and it
is located near the catalytic dyad between domains I andBMC Bioinformatics 2009, 10(Suppl 1):S48 http://www.biomedcentral.com/1471-2105/10/S1/S48
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II. The S1 subsite is a deep hydrophilic pocket and is
located close to Cys145, in part of domain II [7].
The docking energy of the three octapeptides was calcu-
lated. The conformation with the lowest docking energy
from the best cluster (highest of each substrate member)
was selected. The docking energy was a criterion that was
used to judge specificity of the substrate. This meant that,
the lower docking energy referred to a higher specificity.
For comparison, the energies obtained from docking of
each octapeptide are listed in Table 1, showing the
octapeptide P3Lys had an energy of -14.23 kcal/mol. It
had the lowest docking energy so it was the most specific.
Below these were P3Arg and P3Ile, which had docking
energies of -13.26 and -8.11 kcal/mol, respectively.
Hence, the octapeptide P3Ile had the lowest specificity.
The model of the docked structure, as shown in Figure 2,
indicated that the orientation of all of the octapeptides
were similar. Therefore, the decrease in the docking energy
was due to the potential differences in the P3 position of
the octapeptide. It was suggested that an electrostatic
interaction of the Lysine, attracted to a nearby Glutamic
Acid, was the cause. However, the S3 position of the SARS
CoVMpro is composed of two Glutamic Acids (Glu47 and
Glu166). To date, it is not known which Glutamic Acid
interacts with P3Lys. Therefore, this research investigated
this problem by studying the interactions of the enzyme
substrate complex through MD simulations. In addition,
the orientation of the docking octapeptides was superim-
posable over the peptidomimic chloromethyl ketone
inhibitor. This inhibitor was specifically bound to the
SARS CoVMpro in the crystal structure (PDB ID = 1UK4).
Therefore, the structure of the enzyme-substrate complex
obtained from docking studies was acceptable for further
MD simulations.
MD simulations of the interactions between the SARS 
CoVMpro and the octapeptide in form of enzyme-
substrate complexed
The structure of the enzyme-substrate complex (SARS
CoVMpro-octapeptide) obtained from molecular docking
was then subjected to MD simulation. During simulation,
the total energy, the RMSD and the RMSF of the system
were monitored. The total energy is an important criterion
to investigate the equilibrium point and the values
obtained for each system are shown in Figure 3. It is clear
that the system of the enzyme in complex with the
octapeptide rapidly reached equilibrium.
The equilibrium point of this system was about 100 ps.
The average value of the total energy was determined
between 100 and 200 ps. This showed that the energy of
the complex system with octapeptide P3Lys, P3Arg and
Three dimensional structure of the SARS CoVMpro Figure 1
Three dimensional structure of the SARS CoVMpro. The structures were shown in dimer form (a) and monomer form 
(b). The structure was extracted at the equilibrium point of MD simulation. The active site is shown in yellow surface and it is 
separated into the S and S' sites.
Table 1: The docking energy. The energies obtained from the 
interactions between the SARS CoVMpro and the octapeptide 
substrates.
Rank Name Sequencea Docking energy (kcal/mol)
1 P3Lys TVKLQAGF -14.23
2 P3Arg TVRLQAGF -13.26
3 P3Ile TVILQAGF -8.11
a Mutated residues are underlinedBMC Bioinformatics 2009, 10(Suppl 1):S48 http://www.biomedcentral.com/1471-2105/10/S1/S48
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P3Ile were -104521, -104482 and -104216 kcal/mol,
respectively. These results showed that the complex of
octapeptide P3Lys had the lowest energy, whereas P3Ile
had the highest energy. In contrast to the enzyme free
form, the results of the total energy value was unstable in
the first 1500 ps. The values changed distinctly in the first
100 ps and then reached a stable level up to 500 ps. After
this time, the values were changed again by first increasing
and then decreasing until 1500 ps. However, the values
reached an equilibrium level at nearly 2000 ps. From
these results, we have suggested that the variation of the
total energy in the enzyme free form is caused by move-
ment of the flexible chain, one turn α-helix and long loop,
in the active site of the SARS CoVMpro. On the other
hand, in the active site of the SARS CoVMpro complex, the
octapeptide contributed to maintaining the conformation
of the enzyme. To examine this further, the motion of the
octapeptides was also investigated.
The RMSD values versus simulation time are shown in
Figure 4. The RMSD values of all octapeptides were dra-
matically increased in the first 100 ps. After this time, the
values of P3Lys stabilized, whereas the values of the P3Arg
and P3Ile continued to increase and reached a stable level
after nearly 500 ps. After 500 ps, all of values were stable
until the end of simulation. In the stable period, the mean
of the RMSD values of P3Lys, P3Arg and P3Ile were 0.23,
0.33 and 0.34, respectively. These values indicated that,
the structures of the octapeptide in the stable period had
moved slightly when compared to the starting structure.
It is possible to interpret from the results that the variabil-
ity in the first 100 ps was due to the structure of the
octapeptides adapting, after which the P3Lys was a close
fit to the active site cleft of the SARS CoVMpro. After this
time, the octapeptide P3Arg and P3Ile were still not in the
correct confirmation for the active site cleft and they
moved about 0.3–0.35 nm away. However, it is also pos-
sible to suggest that the movement was only happening
on some of the residues of the octapeptide, because the
Time dependence of the RMSD from MD simulation Figure 4
Time dependence of the RMSD from MD simulation. 
The lines of the SARS CoVMpro free form, complexed with 
octapeptide P3Lys, P3Arg and P3Ile were colored in black, 
blue, red and green, respectively.
Molecular docking of the octapeptide substrate Figure 2
Molecular docking of the octapeptide substrate. The 
docking performed through superimposition between the 
hexapeptide chloromethyl ketone inhibitor (red ball and 
stick) and the octapeptide (green stick).
Time dependence of the total energy from MD simulation Figure 3
Time dependence of the total energy from MD simu-
lation. The lines of the SARS CoVMpro free form, com-
plexed with octapeptide P3Lys, P3Arg and P3Ile were 
colored in black, blue, red and green, respectively.BMC Bioinformatics 2009, 10(Suppl 1):S48 http://www.biomedcentral.com/1471-2105/10/S1/S48
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RMSD values stabilized after 500 ps. This indicated that
some residues of P3Arg and P3Ile remained in the active
site cleft.
Movement investigation of the amino acids involved with 
the interactions between the SARS CoVMpro and the 
octapeptide
The RMSF of the enzyme and the octapeptide has also
been investigated. This criterion could describe which res-
idues were either moving or fixed during simulation. The
values were calculated by averaging movement in the
equilibrium period from a time of 500–2000 ps of simu-
lation. The results shown in Figure 5 demonstrate that the
fluctuation of the amino acids in the active site (highlight
of the amino acid residues number) of the enzyme com-
plexed with P3Lys (Figure 5A), were lower than with the
other octapeptide complexes or the free form. The RMSF
in the enzyme complexed with P3Arg also had low values,
but these were still greater than those seen for P3Lys (Fig-
ure 5B). This is in contrast to the RMSF values in complex
with P3Ile (Figure 5C) which they still remain high values.
However, the value of the long loop chain (right high-
light) is seen to be consistent for all structures. The results
also indicated that in the enzyme free form (Figure 5D)
the one turn α-helix moved during simulation, which is in
contrast to the enzyme complexed with octapeptide
P3Lys, where the one turn α-helix chain maintained its
position. From the results of MD simulations, it was
found that the octapeptides in which P3 is either Lys or
Arg have not fallen out of the active site of SARS CoVMpro
during simulation. At the first time period of MD simula-
tions, these P3 have their side chains pointed out to sol-
vent and that after the observed conformational changes
these would then point upward to Glu47, and not down-
ward to Glu166. The results also found that, at equilibra-
tion of MD simulations, an electrostatic interaction was
formed between S3Glu47 and P3Lys or P3Arg with a dis-
tance of 3.5–5.0 Å.
We found the Glu166 could not generate the electrostatic
interaction with the octapeptide P3 because it was neutral-
ized with a salt bridge to Ser1 of monomer B. However,
The P3Lys was bound more specifically than P3Arg due to
the steric hindrance effect of the planar Arg side chain. The
hydrogen bonds, water-bridges and electrostatic interac-
tions between S3Glu47 and P3Lys (Arg) have been
observed continuously until the end of MD simulation
times. This phenomenon has not been previously
reported and this research can propose that the character-
istic of S3Glu47, with the negatively charged region it gen-
erates, is important for the binding mechanism of SARS
CoVMpro.
The hydrogen bonds of the enzyme-substrate complex
The number of hydrogen bonds seen within the simula-
tion time fluctuates between 4–7 (Figure 6), which indi-
cated that there were always 4–7 hydrogen bonds between
the SARS CoVMpro and the octapeptide. However, the
enzyme-substrate complexed could form 9 hydrogen
bonds at P5Thr(N-terminus)---S5Gln191, P4Val(back-
bone)---S5Thr190, P4Val(backbone)---Thr191, P3Lys---
S3Glu47, P1Gln---S1His163, P1Gln---Ser144, P3'Phe---
S4Thr21, P3'Phe---S4Thr24 and P3'Phe---S4Thr26. These
Hydrogen bonds number between the SARS CoVMpro and  the octapeptide Figure 6
Hydrogen bonds number between the SARS CoVM-
pro and the octapeptide. The octapeptide P3Lys, P3Arg 
and P3Ile were shown in A, B and C, respectively.
The RMSF with respect to amino acid residues of the SARS  CoVMpro Figure 5
The RMSF with respect to amino acid residues of the 
SARS CoVMpro. The values were calculated averaging at 
time range 500–2000 ps of MD simulation. The values of the 
SARS CoVMpro complexed with octapeptide P3Lys, P3Arg 
and P3Ile were shown in A, B and C, respectively. The value 
of the SARS CoVMpro free form was shown in D. The 
shadow region from left to right represent the region of pro-
tein chain namely one turn α-helix (residues 47–54) and long 
loop (residues 184–192) of SARS CoVMpro, respectively.BMC Bioinformatics 2009, 10(Suppl 1):S48 http://www.biomedcentral.com/1471-2105/10/S1/S48
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bonds may be involved in ensuring effective binging of
the octapeptide to the active site of the SARS CoVMpro.
Conclusion
The MD simulation results and the number of hydrogen
bonds formed in the SARS CoVMpro-octapeptide com-
plex have been obtained. These results indicate clearly
that the S3 subsite of the SARS CoVMpro has a negative
character. The hypothesis proposed that Glu47 is an
important residue in the S3 subsite for binding with P3Lys
of the octapeptide. The electrostatic interactions between
Glu47 and P3Lys play a key role in specific binding. These
observations are very important and provide further infor-
mation for structural-based drug design against SARS
virus.
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